Lexeo Therapeutics, Inc. Common Stock
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $397.3M
- Price
- $5.06
- % Change (Daily % change from the live per-ticker quote feed.)
- -5.77%
- Volume
- 1.1M
About
Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical development phase, dedicated to addressing both inherited and acquired medical conditions. Its robust pipeline features several gene therapy candidates. These include LX2006, an AAVrh10-based therapy aimed at treating cardiomyopathy linked to Friedreich's ataxia (FA); LX2020, another AAVrh10-based candidate targeting arrhythmogenic cardiomyopathy; LX2021, designed for DSP cardiomyopathy; and LX2022, which focuses on hypertrophic cardiomyopathy (HCM) stemming from TNNI3 mutations. Furthermore, Lexeo is advancing LX1001, an AAVrh10-based gene therapy, alongside LX1020 and LX1021, all intended for individuals homozygous for APOE4. Additionally, LX1004 is under development to treat CLN2 Batten disease. Established in 2017, the company's headquarters are located in New York, New York.
Quick stats
Shares outstanding78.5M
Computed float76.6M
Float / shares97.6%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001907108
Websitehttps://www.lexeotx.com
AI Summary
AI-generated1/15
standardbullishearnings
Lexeo Therapeutics Reports Second Quarter 2026 Financial Results and Operational Highlights
Lexeo reported a Q2 net loss of $0.30 per share, with R&D expenses increasing to $19.0 million as the company advanced its pipeline, ending the quarter with a strong cash position of $234.2 million expected to fund operations into 2028.
Operationally, the company initiated the pivotal SUNRISE-FA 2 trial for LX2006 in Friedreich ataxia cardiomyopathy in June, with topline data anticipated in the second half of 2027.
Additionally, the FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation for LX2020 in PKP2 arrhythmogenic cardiomyopathy, a milestone that should expedite development and increase FDA interaction.